Christoph B Olivier1, Patrick Weik2, Melanie Meyer2, Susanne Weber3, Nathaly Anto-Michel2, Philipp Diehl2, Qian Zhou2, Ulrich Geisen4, Christoph Bode2, Martin Moser2. 1. Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany. Electronic address: Christoph.Olivier@universitaets-herzzentrum.de. 2. Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany. 3. Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany. 4. Medical Center-University of Freiburg, Institute for Clinical Chemistry and Laboratory Medicine, Freiburg, Germany.
Abstract
BACKGROUND/ OBJECTIVES: Novel (or non-vitamin K antagonist) oral anti-coagulants (NOACs) are antagonists of coagulation factors (F) Xa (rivaroxaban) or IIa (dabigatran), and their non-inferiority compared with vitamin K antagonists has been demonstrated in patients with non-valvular atrial fibrillation. However, it is still not fully understood if and how dabigatran and rivaroxaban impact platelet function. This observational study aimed to assess platelet function in patients receiving dabigatran or rivaroxaban. METHODS/ RESULTS: This was a single centre, observational study quantifying platelet aggregation in 90 patients treated with NOACs by multiple electrode aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly higher in 35 patients receiving dabigatran (d) compared with control (c) patients (d 108±31 vs. c 85±30arbitrary units [AU]∗min, p<0.001). Patients receiving rivaroxaban (r) showed no differences compared with the control group (r 88±32 vs. c 85±30AU∗min, p=0.335). In intraindividual time courses of 16 patients, a significantly higher aggregation was found after the administration of dabigatran (before vs. after; 83±29 vs. 100±31AU∗min, p=0.009). CONCLUSION: In this observational study, the TRAP-induced platelet aggregation was enhanced in cardiovascular patients receiving dabigatran. This might be explained by a change in the expression profile of thrombin receptors on the surface of platelets. Rivaroxaban had no influence on platelet aggregation.
BACKGROUND/ OBJECTIVES: Novel (or non-vitamin K antagonist) oral anti-coagulants (NOACs) are antagonists of coagulation factors (F) Xa (rivaroxaban) or IIa (dabigatran), and their non-inferiority compared with vitamin K antagonists has been demonstrated in patients with non-valvular atrial fibrillation. However, it is still not fully understood if and how dabigatran and rivaroxaban impact platelet function. This observational study aimed to assess platelet function in patients receiving dabigatran or rivaroxaban. METHODS/ RESULTS: This was a single centre, observational study quantifying platelet aggregation in 90 patients treated with NOACs by multiple electrode aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly higher in 35 patients receiving dabigatran (d) compared with control (c) patients (d 108±31 vs. c 85±30arbitrary units [AU]∗min, p<0.001). Patients receiving rivaroxaban (r) showed no differences compared with the control group (r 88±32 vs. c 85±30AU∗min, p=0.335). In intraindividual time courses of 16 patients, a significantly higher aggregation was found after the administration of dabigatran (before vs. after; 83±29 vs. 100±31AU∗min, p=0.009). CONCLUSION: In this observational study, the TRAP-induced platelet aggregation was enhanced in cardiovascularpatients receiving dabigatran. This might be explained by a change in the expression profile of thrombin receptors on the surface of platelets. Rivaroxaban had no influence on platelet aggregation.
Authors: B Steppich; F Dobler; L C Brendel; G Hessling; S L Braun; A L Steinsiek; I Deisenhofer; A Hyseni; M Roest; I Ott Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300
Authors: Christoph B Olivier; Patrick Weik; Melanie Meyer; Susanne Weber; Philipp Diehl; Christoph Bode; Martin Moser; Qian Zhou Journal: J Thromb Thrombolysis Date: 2016-08 Impact factor: 2.300
Authors: Jonathan Rilinger; Melanie Meyer; Katharina Schnabel; Patrick Weik; Anne Charlet; Jennifer S Esser; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl; Christoph B Olivier Journal: J Thromb Thrombolysis Date: 2016-11 Impact factor: 2.300
Authors: Diona Gjermeni; Hannah Vetter; Sofia Szabó; Viktoria Anfang; Stefan Leggewie; David Hesselbarth; Daniel Duerschmied; Dietmar Trenk; Christoph B Olivier Journal: J Clin Med Date: 2022-07-21 Impact factor: 4.964
Authors: Sophie C Dólleman; Stijn M Agten; Henri M H Spronk; Tilman M Hackeng; Mettine H A Bos; Henri H Versteeg; Anton Jan van Zonneveld; Hetty C de Boer Journal: J Thromb Haemost Date: 2022-02-02 Impact factor: 16.036
Authors: Christoph B Olivier; Melanie Meyer; Hans Bauer; Katharina Schnabel; Patrick Weik; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl Journal: PLoS One Date: 2016-02-17 Impact factor: 3.240